| Writing Group Disclosures | ||||||||
|---|---|---|---|---|---|---|---|---|
| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
| Ralph L. Sacco | University of Miami | NINDS† | None | None | None | None | DSMB (Atrial Fibrillation Trial–institutionally sponsored by PHRI Hamilton, Ontario)* | None |
| Scott E. Kasner | University of Pennsylvania | Gore Associates† | None | None | None | None | AstraZeneca*; BrainsGate (DSMB)*; CardioNet*; Medtronic DSMB*; Novartis*; Parexel*; Pfizer* | None |
| Joseph P. Broderick | University of Cincinnati | NINDS† | None | Oakstone Publishing* | None | None | Genentech*; PhotoThera DSMB* (All consultant fees are placed in educational/research fund for UIC Department of Neurology) | None |
| Louis R. Caplan | Beth Israel Deaconess Medical Center | None | None | AstraZeneca*; Boehringer-Ingelheim*; Bristol-Myers-Squibb*; Otsuka*; Sanofi-Synthelabo* | None | None | ARUBA Trial (Endpoint Adjudication Committee) NINDS*; AstraZeneca*; Avanir Pharmaceuticals*; Bayer Schering Pharma*; Boehringer-Ingelheim*; CoAxia*; Genentech*; Jones & Davis, LLP*; LifeCycle Pharma A/S*; Lytics Lifecycle*; NeuroLogica*; Novo Nordisk*; NovoVision*; Micromedex*; Millennium Pharma*; ReNeuron*; SAMPRISS Trial (Endpoint Adjudication Committee) NINDS*; Takeda Pharma* | Editorial boards: Reviews in Neurological Diseases (Editor)*; Archives of Neurology* |
| J.J. (Buddy) Connors | Vanderbilt University Medical Center | None | None | None | None | None | None | None |
| Antonio Culebras | Upstate Medical University (New York) | None | None | None | J Uriach Foundation* | None | Member WHO Advisory Group for Revision of ICDS-10, sleep disorders* | Editorial boards: Reviews in Neurological Diseases (Associate Editor)*; MedLink (Associate Editor)*; AAN Guideline Update, Atrial Fibrillation panel (Chair)*; AAN Stroke Section (Chair-elect)* |
| Mitchell S.V. Elkind | Columbia University | Bristol-Myers Squibb-Sanofi Partnership*; diaDexus, Inc*; NHLBI†; NIH/NINDS† (NOMAS–PI; LIMITS–PI; NeuSTART–PI; VIPS–Co-I; VERITAS–Co-I; SAMMPRIS–Co-I; SPS3–Co-I; ERICH–Co-I; California Teachers Study–Co-I) | None | Bristol-Myers Squibb-Sanofi Partnership*; Boehringer-Ingelheim*; Genentech* | GlaxoSmithKline* (Avandia defense); Novartis (Zelnorm defense)† | None | GlaxoSmithKline*; Tethys Biosciences* | None |
| Mary G. George | Centers for Disease Control and Prevention | None | None | None | None | None | None | None |
| Allen D. Hamdan | Beth Israel Deaconess Medical Center | None | None | None | None | None | None | None |
| Randall T. Higashida | University of California at San Francisco | None | None | None | None | None | None | None |
| Brian L. Hoh | University of Florida | Brain Aneurysm Foundation†; Micrus Endovascular*; NIH†; Thomas H. Maren Foundation† | None | None | None | None | Actelion Pharmaceutical*; Codman Neurovascular* | None |
| L. Scott Janis | NINDS/NIH/DHHS | None | None | None | None | None | None | None |
| Carlos S. Kase | Boston University Medical Center | NIH† | None | None | None | None | Ferrer International*; Sanofi-Aventis* | None |
| Dawn O. Kleindorfer | University of Cincinnati | AAMC/CDC†; NIH/NINDS†; NIH†; NIH/Yale† | None | Genentech* | None | None | Boehringer-Ingelheim* | None |
| Jin-Moo Lee | Washington University School of Medicine | AGA Medical†; Barnes-Jewish Hospital Foundation†; NIA†; NHLBI†; NINDS† | AstraZeneca† | None | None | None | None | None |
| Michael E. Moseley | Stanford University | NINDS† | None | None | None | None | None | None |
| Eric D. Peterson | Duke University | Bristol-Myers Squibb-Sanofi†; Johnson & Johnson†; Lilly†; NIH†; Merck/Schering† | None | None | None | None | None | None |
| Tanya N. Turan | Medical University of South Carolina | NIH†; NIH/NINDS† | None | None | None | None | Boehringer-Ingelheim Pharma GmbH & Co*; Gore & Associates*; NIH * | None |
| Amy L. Valderrama | Centers for Disease Control and Prevention | None | None | None | None | None | None | None |
| Harry V. Vinters | David Geffen School of Medicine at University of California, Los Angeles, and Ronald Reagan UCLA Medical Center, Los Angeles | National Alzheimer Coordinating Center (NACC) †; NINDS†; State of California, Pediatric Neuropathology Consortium, member†; UCLA Alzheimer Disease Research Center†; UCLA SPOTRIAS grant† | Translational Research Fund, UCLA Department of Pathology* | Occasional CME talks (2–3 annually), Los Angeles–area hospitals* | Beasley & Demos – cerebral cortical malformation case for defense*; Dummit, Buchholz & Trapp – review autopsy slides for wrongful death case for defense*; Kralovec, Jambois & Schwartz – pituitary adenoma case for defense*; Krupnick, Campbell & Malone – incorrect diagnosis of brain tumor case for plaintiff*; LaFollette, Johnson, DeHaas, Fesler & Ames – AVM case for defense*; Lewis, Brisbois, Bisgaard & Smith – age and nature of neuropathologic changes case for defense*; McKeen & Associates, P.C. - review autopsy for fatal cerebral edema with hyponatremia case for defense*; Murphy, Pearson, Bradley & Feeney – subdural hematoma case for defense*; Reback, McAndrews, Kjar, Warford & Stockalper, LLP – autopsy evaluation for Alzheimer disease case for defense*; Steven L. Saldo – spontaneous cerebral hemorrhage case for defense*; Skiver & Associates – wrongful death caused by anesthetic error leading to neurologic complications case for defense*; Snyder & Wenner, P.C. – autopsy review for wrongful death related to seizures case for defense* | Becton Dickinson†; General Electric (medical and imaging equipment)†; GlaxoSmithKline†; Pfizer†; Teva Pharmaceuticals†; 3M (medical equipment and supplies)† | ESAB*; Indiana Alzheimer Center*; Massachusetts ADRC*; HIV Neurobehavioral Research Center (San Diego, UCSD)* | Editorial boards: Neuropathology and Applied Neurobiology*; Neuropathology*; Korean Journal of Pathology*; Journal of Neuroscience Research*; Human Pathology* |
| Reviewer Disclosures | ||||||||
|---|---|---|---|---|---|---|---|---|
| Reviewer | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
| Harold P. Adams | University of Iowa | NINDS*; St. Jude* | None | None | None | None | None | None |
| Gregory W. Albers | Stanford University | None | None | None | None | None | None | None |
| Robert Brown | Mayo Clinic | None | None | None | None | None | None | None |
| Creed Pettigrew | University of Kentucky | None | None | None | None | None | None | None |
| Lee H. Schwamm | Massachusetts General Hospital | None | None | None | None | None | LifeImage*; Lundbeck DIAS-4 International Steering Committee* | Chair, GWTG national steering committee (unpaid)* |
| Babu Welch | UT Southwestern Medical Center | None | None | None | None | None | None | None |
| Philip A. Wolf | Boston University | None | None | None | None | None | None | None |
| Allyson Zazulia | Washington University | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.